Related Experiment Video
Updated: May 5, 2026
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Controlling CAR-T cell activity and specificity with synthetic SparX adapters
Justin P Edwards1, Jeffrey S Swers1, Janine M Buonato1
1Arcellx, Inc, Rockville, MD 20850, USA.
Abstract:
While conventional chimeric antigen-receptor (CAR)-T therapies have shown remarkable clinical activity in some settings, they can induce severe toxicities and are rarely curative. To address these challenges, we developed a controllable cell therapy where synthetic D-domain-containing proteins (soluble protein antigen-receptor X-linker [SparX]) bind one or more tumor antigens and mark those cells for elimination by genetically modified T cells (antigen-receptor complex [ARC]-T). The chimeric antigen receptor was engineered with a D-domain that specifically binds to the SparX protein via a unique TAG, derived from human alpha-fetoprotein. The interaction is mediated through an epitope on the TAG that is occluded in the native alpha-fetoprotein molecule. In vitro and in vivo data demonstrate that the activation and cytolytic activity of ARC-T cells is dependent on the dose of SparX protein and only occurs when ARC-T cells are engaged with SparX proteins bound to antigen-positive cells. ARC-T cell specificity was also redirected in vivo by changing SparX proteins that recognized different tumor antigens to combat inherent or acquired tumor heterogeneity. The ARC-SparX platform is designed to expand patient and physician access to cell therapy by controlling potential toxicities through SparX dosing regimens and enhancing tumor elimination through sequential or simultaneous administration of SparX proteins engineered to bind different tumor antigens.
Insights
This study introduces a controllable cell therapy, antigen-receptor complex T (ARC-T) cells, using synthetic SparX proteins to target tumors. This platform enhances tumor elimination and controls toxicity for broader cell therapy access.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Conventional chimeric antigen receptor (CAR)-T therapies show promise but are limited by severe toxicities and lack of curative potential.
- Existing CAR-T cell therapies face challenges in controlling on-target, off-tumor toxicities and addressing tumor heterogeneity.
Purpose of the Study:
- To develop a controllable cell therapy platform, antigen-receptor complex T (ARC-T) cells, that utilizes synthetic SparX proteins for targeted tumor elimination.
- To engineer a system where ARC-T cell activation and cytolytic activity are precisely controlled by SparX protein dosage and tumor antigen binding.
- To enhance therapeutic efficacy by addressing tumor heterogeneity through adaptable SparX protein targeting.
Main Methods:
- Development of synthetic D-domain-containing proteins (SparX) that bind tumor antigens.
- Engineering of chimeric antigen receptors with D-domains that specifically bind SparX proteins via a unique TAG.
- In vitro and in vivo assessment of ARC-T cell activation, cytolytic activity, and specificity in response to SparX protein administration.
- Demonstration of redirectable ARC-T cell specificity by altering SparX proteins to target different tumor antigens.
Main Results:
- ARC-T cell activation and cytolytic activity were found to be dose-dependent on SparX protein levels.
- ARC-T cell engagement and tumor cell elimination occurred only when SparX proteins were bound to antigen-positive cells.
- ARC-T cell specificity was successfully redirected in vivo by switching SparX proteins, demonstrating adaptability to tumor heterogeneity.
- The ARC-SparX platform showed potential for controlling toxicities via SparX dosing and enhancing tumor elimination through multi-antigen targeting.
Conclusions:
- The ARC-SparX platform offers a controllable and adaptable cell therapy approach for cancer treatment.
- This system allows for precise control over T-cell activation, mitigating potential toxicities associated with cell therapies.
- The ability to target multiple antigens sequentially or simultaneously with different SparX proteins holds promise for overcoming tumor heterogeneity and improving treatment outcomes.
